The Best Growth Stocks by Revenue Growth

Stocks with high revenue growth on a TTM basis, sorted by distance to the 52-week high.
Rank Stock Price Rev. Gr. Dist.
52WH
Perf. 20D
WKN | Symbol EPS Growth Rel. Strength
1 Palomar Holdings 130.13 $ 40.22 % 9.49 % -0.24 %
A2PHB6 | PLMR 49.48 % 96
2 HCI Group 137.20 $ 49.16 % 9.67 % -1.52 %
A1W02H | HCI 199.39 % 85
3 Alignment Healthcare 18.84 $ 48.25 % 10.54 % 19.92 %
A2QSBM | ALHC - % 99
4 HEICO 187.93 $ 43.13 % 14.27 % -5.63 %
914043 | HEI/A 19.31 % 87
5 Heico 238.62 $ 43.13 % 15.86 % -5.58 %
889997 | HEI 19.31 % 88
6 StoneX Group 70.30 $ 64.14 % 17.76 % -3.65 %
A2P8CE | SNEX 7.01 % 95
7 Catalyst Pharmaceuticals 20.86 $ 32.17 % 20.27 % -1.62 %
A0LCUL | CPRX 111.86 % 90
8 Newmont 46.64 $ 53.66 % 20.57 % 6.90 %
853823 | NEM - % 83
9 Rhythm Pharmaceuticals 53.57 $ 81.55 % 21.89 % 4.38 %
A2H5A0 | RYTM - % 87
10 Mercadolibre 1,842.40 $ 43.63 % 22.44 % -8.13 %
A0MYNP | MELI 43.98 % 86
Subscribe now to see the full ranking

Already a subscriber? Login

Image 1Image 2Image 3Image 4Image 5
Sample Issue
$ 0
one issue
Bestseller
Trial Subscription
$ 33
1 month
Daniel Dünn

Dear readers, Last week, I introduced five biopharma stocks that have taken off in recent weeks. It became clear that the megatrend "biopharmaceuticals" continues to be one of the most dynamic and promising segments in the stock market. Today, I would like to look a bit further into the future: The five companies I present below have not only increased...

Dr. Philip Bußmann

Rhythm Pharmaceuticals is on the verge of the first approval for rare hypothalamic obesity – a billion-dollar market with little competition. Oral and weekly variants in the pipeline ensure long-term market shares and growth potential. Rhythm Pharmaceuticals (NASDAQ: RYTM) is purposefully advancing into a field that is barely recognized...